Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on sequencing targeted therapies.
Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear ...
Goldman Sachs analyst Chris Shibutani adjusted the price target for Merck (NSE:PROR) & Co. Inc. (NYSE:MRK) to $129.00, down from the previous $135.00, while reiterating a Buy rating on the ...
Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused ...
The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.
MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback